Company intelligence / Profile preview
DemeRx NB
Miami, Florida, United Statesdemerx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DemeRx NB is a clinical-stage biotechnology company focused on developing noribogaine for the treatment of opioid use disorder (OUD). A joint venture between DemeRx and ATAI Life Sciences, the company is advancing DMX-1002 (noribogaine), a non-hallucinogenic active metabolite of ibogaine, as a potential disease-modifying treatment for addiction. The program aims to reduce withdrawal symptoms and cravings, providing a bridge to long-term recovery for patients transitioning off opioids. By focusing on the pharmacology of noribogaine, DemeRx NB seeks to offer a safer and more regulated alternative to traditional ibogaine treatments.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ATAI Life SciencesDemeRx
Beyond the preview
Go deeper on DemeRx NB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DemeRx NB.